10 registrations that name beta-glucans as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 10 registrations
Status
Phase
11US sites across 4 states
1
2 to 4
5 to 19
20 or more
All 10 registrations
RecruitingNCT06057948
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Phase 2
Memorial Sloan Kettering Cancer Center
About 100 people
Started Sep 21, 2023
In plain words A Phase 2 study of beta-glucans in people of any age, run by Memorial Sloan Kettering Cancer Center. It plans to enroll about 100 people at 7 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people of any age. Conditions: Neuroblastoma; High-risk Neuroblastoma; Metastatic Neuroblastoma.
Diagnosis of NB as defined by international criteria,102 i.e., histopathology (confirmed by the MSK Department of Pathology) or BM metastases plus high urine catecholamine levels, or positivity in MIBG scan.
HR-NB as defined by risk-related treatment guidelines and international criteria,102 i.e., metastatic/non-localized disease with MYCN amplification (any age), metastatic disease >18 months old, MYCN-amplified localized disease (any age),…
HR-NB (as defined above) and in 1) first CR at ≥ 6 months from initiation of immunotherapy using anti-GD2 antibody, or 2) second or subsequent CR (achieved after treatment for PD).
Patients with grade 3 toxicities or less using the Common Toxicity Criteria (Version 5.0) developed by the National Cancer Institute of the USA (CTCAE v5.0) related to hematologic, cardiac, neurological, pulmonary, renal, hepatic or…
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
OPT-821 (QS-21); oral β-glucan
Registered summary
The purpose of this study is to test which treatment schedule of β-glucan with bivalent vaccine is more effective for participants with high-risk neuroblastoma that is in complete remission.
Where, as registered
7 US sites in 2 states.
RecruitingNCT00682032
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
No phase
University of Louisville
About 300 people
Started Oct 2008
In plain words A study of beta-glucans in people 18 and older, run by University of Louisville. It plans to enroll about 300 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Non Small Cell Lung Cancer.
suspected or definitive diagnosis of non-small cell lung cancer (NSCLC)
treatment naive or no treatment within 6 months prior to enrollment
able to swallow pills
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
beta-glucan
Registered summary
The purpose of this study is to determine how beta-glucan affects the immune system in subjects with non-small cell lung cancer.
Where, as registered
1 US site in 1 state.
RecruitingNCT04936529
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Phase 2
Memorial Sloan Kettering Cancer Center
About 286 people
Started Aug 2, 2021
In plain words A Phase 2 study of beta-glucans in people of any age, run by Memorial Sloan Kettering Cancer Center. It plans to enroll about 286 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people of any age; healthy volunteers accepted. Conditions: Neuroblastoma.
Diagnosis of NB as defined by international criteria, i.e., histopathology (confirmed by the MSK Department of Pathology) or BM metastases plus high urine catecholamine levels or positivity in MIBG scan
HR-NB as defined by risk-related treatment guidelines and international criteria,i.e., metastatic/non-localized disease with MYCN amplification (any age), MYCN-non-amplified metastatic disease >18 months old, MYCNamplified localized…
HR-NB (as defined above) and in 1) first CR at ≥ 6 months from initiation of immunotherapy using anti-GD2 antibody, or 2) second or subsequent CR (achieved after treatment for PD).
Patients with grade 3 toxicities or less using the Common Toxicity Criteria (Version 5.0) developed by the National Cancer Institute of the USA (CTCAE v5.0) related to hematologic, cardiac, neurological, pulmonary, renal, hepatic or…
16 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
β-glucan; GM-CSF; OPT-821
Registered summary
The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF) as an effective treatment for people with high-risk neuroblastoma that is in complete remission. The combination may be effective because the different parts of the treatment work to strengthen the immune system's response against cancer cells in different ways.
Where, as registered
1 US site in 1 state.
RecruitingNCT07305259
Researching Economical Adjuvants to Cancer Therapy
Early phase 1
Florida State University
About 60 people
Started Nov 12, 2025
In plain words An early phase 1 study of beta-glucans in people 18 to 45, run by Florida State University. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45; healthy volunteers accepted. Conditions: Healthy Participants.
Physically fit enough to engage in maximal exercise.
The exclusion criteria are on the listing.
What it tests, as registered
Beta-glucan; Placebo
Registered summary
The goal of this clinical trial is to learn if beta-glucan (a dietary fiber) improves the function of the immune system in adults. It will also tell the investigators if combining beta-glucan with single bouts of exercise provides additional benefit. The main questions it aims to answer are: 1. Does beta-glucan change the ability of immune cells to recognize cancer cells? 2. Does exercise change the type of immune cells in the blood? Researchers will compare beta-glucan to a placebo (a look-alike substance with no effect) to see if beta-glucan could improve immune function against cancer. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT04513028
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
No phase
Kelly McMasters
About 30 people
Started Nov 3, 2020
In plain words A study of beta-glucans in people 18 and older, run by Kelly McMasters. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Melanoma Stage III; Melanoma Stage IV.
Any patients with suspected (clinical) or definitive (tissue) diagnosis of Stage III-IV melanoma starting or continuing adjuvant Pembrolizumab without active evidence of disease (NED).
Must be treatment naïve or have had treatment no less than 6 months prior to enrollment
18 years or older
Must be able to take pills
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Beta-Glucan
Registered summary
The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.
Where, as registered
1 US site in 1 state.
RecruitingNCT06861062
Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes
No phase
Huazhong University of Science and Technology
About 2,500 people
Started Apr 8, 2025
In plain words A study of beta-glucans in people 40 to 79, run by Huazhong University of Science and Technology. It plans to enroll about 2,500 people at 5 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 79. Conditions: Diabetes Mellitus, Type 2.
Type 2 diabetes mellitus diagnosed by a physician based on the diagnostic criteria outlined in the Guideline for the Prevention and Treatment of Diabetes Mellitus in China (2024 Edition);
Men or women aged 40-79 years;
Convenient access to the study centers and permanent residence in the vicinity for the next five years;
Voluntary participation and signed written informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
Vitamin D3; yeast β-glucan; Vitamin D placebo; yeast β-glucan placebo
Registered summary
This study is a randomized, double-blind, placebo-controlled trial involving 2,500 individuals aged 40-79 with type 2 diabetes (T2D). The trial includes a 2-year intervention period followed by a 3-year post-intervention follow-up. The primary objective is to investigate (a) the effect of daily supplementation with vitamin D3 (1600 IU) or yeast β-glucan (600 mg) on glycemic control in patients with T2D and (b) whether daily supplementation with vitamin D3 (1600 IU) or yeast β-glucan (600 mg) reduces the predicted 10 year risk of atherosclerotic cardiovascular disease (ASCVD) in patients with… The full summary is on the listing.
Where, as registered
No US site; China (5).
RecruitingNCT07299942
Impact of Beta-glucan Supplementation During Calorie and Carbohydrate-restricted Diet on Body Weight and Body Fat Loss, Appetite, and Gastrointestinal Appetite Hormones.
No phase
University of Glasgow
About 60 people
Started Jul 1, 2024
In plain words A study of beta-glucans in female participants 18 to 60, run by University of Glasgow. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 60; healthy volunteers accepted. Conditions: Overweight and Obese Women.
Healthy females living with overweight or obese (BMI of 25 - 39.9 kg/m2).
Age between 18 to 60 years.
Stable body weight for at least 3 months preceding the study.
The exclusion criteria are on the listing.
What it tests, as registered
Beta-glucan addition to a restricted calorie of meal replacements and carbohydrate diet.; Cellulose (Placebo) addition to a restricted calorie of meal replacements and carbohydrate diet.
Registered summary
This study will investigate whether beta-glucan supplementation, when added to an energy and carbohydrate-restricted diet, facilitates body weight and body fat loss, and leads to less detrimental changes in subjective appetite and gastrointestinal appetite hormones. This will be a double-blind, randomised, controlled trial in which healthy females living with overweight and obesity will be randomly assigned to a beta-glucan or a cellulose (placebo) group (1:1 basis). The randomisation software will be used to generate a randomisation list. The full summary is on the listing.
Where, as registered
No US site; United Kingdom (1).
Not yet recruitingNCT05364736
Effect of Prebiotics on Blood Pressure Management
No phase
Sun Yat-sen University
About 100 people
Starts Oct 17, 2022 (estimated)
In plain words A study of beta-glucans in people 30 to 65, run by Sun Yat-sen University. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 30 to 65; healthy volunteers accepted. Conditions: Hypertension; Gastrointestinal Microbiome.
Age:30-65 years old
Newly diagnosed hypertension did not use antihypertensive drugs OR Systolic blood pressure ≥140mmHg on the physical examination OR Diastolic blood pressure ≥90mmHg on the physical examination.
This survey is designed to investigate the effect of highland barley β-glucan supplementation on the regulatory of blood pressure, gut microbiota and cardiovascular risk fators in subjects with hypertention.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07085858
Study of the Preventive Effects and Mechanisms of Yeast β-Glucan on Upper Respiratory Tract Infections
No phase
LanZhou University
About 96 people
Starts Jul 25, 2025 (estimated)
In plain words A study of beta-glucans in people 18 to 35, run by LanZhou University. It plans to enroll about 96 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 35. Conditions: Upper Respiratory Tract Infections.
Aged between 18 and 35 years;
Meeting the symptom criteria for persistent allergic rhinitis (AR) as defined in the Chinese Guidelines for Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition): (1) Symptoms: Two or more of the following-paroxysmal…
No use of probiotics, prebiotics, synbiotics, antihistamines, corticosteroids, or immunosuppressants within 1 month prior to screening;
Willing and able to maintain usual physical activity levels and dietary patterns during the study;
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
yeast β-glucan; placebo
Registered summary
This study is designed as a randomized, double-blind, placebo-controlled human intervention trial targeting a population of university students with persistent allergic rhinitis (AR) symptoms. The primary objective is to evaluate the preventive effect and underlying mechanisms of yeast β-glucan on upper respiratory tract infections (URTIs), providing scientific evidence for the prophylactic use of prebiotics in high-risk populations. All participants will be stratified by sex and body mass index (BMI), and then randomly assigned to either the yeast β-glucan group or the control group. The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07366749
Acute Effects of a Urate-lowering Bacterial Therapeutic on Small Intestinal Transcriptomics and Glycomics in Healthy Subjects
No phase
Örebro University, Sweden
About 8 people
Starts Feb 2026 (estimated)
In plain words A study of beta-glucans in people 18 to 60, run by Örebro University, Sweden. It plans to enroll about 8 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60; healthy volunteers accepted. Conditions: Healthy; Hyperuricemia, Gout.
Signed informed consent.
Age 18-60 years.
BMI 18.5 - 29.9 kg/m².
Willing to avoid probiotics, fermented foods, and maintain stable diet/lifestyle for the study duration.
This is a pilot study investigating how a novel probiotic supplement (BEO001), with and without a dietary fiber (beta-glucan), affects the lining of the small intestine in healthy people. The main goal is to see if a single dose of the probiotic changes gene activity (transcriptomics) and sugar molecule patterns (glycomics) in the gut. Eight participants will take three different treatments (placebo, probiotic alone, probiotic with fiber) in a random order, with at least 10 days between each. The full summary is on the listing.